• 3 days How To Invest In The Cybersecurity Boom
  • 5 days Investors Are Patient With Unprofitable Giants
  • 7 days Wells Fargo Back In The Scandal Spotlight Once Again
  • 9 days 5 Stocks To Keep A Close Eye On This Year
  • 10 days As Auto Giants Flail, Look To Chip Stocks For Gains
  • 11 days Central America Is Ready For The Bitcoin Hustle
  • 13 days China’s Video Game Restrictions Unlikely To Slow Down Booming Industry
  • 14 days Top Performing Stocks As Inflation Fears Grow
  • 15 days US Airline Stocks Take A Beating On New EU Restrictions
  • 16 days This IPO Could Open Sustainable Fashion Floodgates
  • 17 days Crypto Crime Nets Another $2B Fraudster
  • 19 days This Week’s Hottest Meme Stocks
  • 20 days Why World Markets Should Be Watching Germany Closely
  • 22 days Could ‘Cultured’ Meat Rival The Plant-Based Megatrend?
  • 25 days ‘Easy Money’: Crypto Is Still Attracting Newbie Investors
  • 26 days Foreign Syndicates May Have Stolen Up To $400B In COVID Benefits
  • 27 days Gold Jumps Above $1800 Ahead Of Jackson Hole Summit
  • 27 days International Banks Blacklist Afghanistan Following Taliban Takeover
  • 29 days China’s Tycoons Are Getting A Serious Reality Check
  • 30 days U.S. Cannabis Space Heats Up With Telling Tilray Acquisition
  1. Home
  2. News
  3. Breaking News

SEC Cracks Down On Silicon Valley’s “Disruptive Tech”

SEC

The SEC has laid fraud charges against the CEO of a company that once had a $9-billion valuation and was a darling of Silicon Valley thanks to its portable blood analyzer which claimed to be so revolutionary it was used by the Department of Defense on the battlefields of Afghanistan.

Except that it wasn’t, and now the U.S. Securities and Exchange Commission is striking back with massive fraud charges.

On Wednesday, Elizabeth Holmes, the founder and CEO of Theranos was charged for running an “elaborate, years-long fraud” by the SEC, which accused her and partner Ramesh “Sunny” Balwani, of having “allegedly deceived investors into believing that its key product—a portable blood analyzer—could conduct comprehensive blood tests from finger drops of blood.”

The DoD, it turns out, never used Theranos products or its purportedly proprietary technology, though it was at one point touted by U.S. Central Command head General Jim Mattis, who later joint the Theranos board before becoming U.S. Secretary of Defense.

According to the SEC, “Holmes, and Balwani claimed that Theranos’ products were deployed by the U.S. Department of Defense on the battlefield in Afghanistan and on medevac helicopters and that the company would generate more than $100 million in revenue in 2014. In truth, Theranos’ technology was never deployed by the U.S. Department of Defense and generated a little more than $100,000 in revenue from operations in 2014.”

“It’s an important lesson for Silicon Valley,” SEC San Francisco direction Jina Choi said in a separate statement. “Innovators who seek to revolutionize and disrupt an industry must tell investors the truth about what their technology can do today, not just what they hope it might do someday.” Related: The Race To Bring WiFi To The World

According to the SEC, Holmes raised more than $750 million between late 2013 and 2015 on fraudulent claims. But in reality, the SEC alleged, “Theranos was able to process just a small number of blood tests upon its proprietary analyzer, and instead conducted the vast majority of its patients’ tests on modified commercial analyzers that were manufactured by others.”

The SEC charges come two years after an investigation prompted by the Wall Street Journal.

So what happens now, other than a lesson for Silicon Valley that not even a handful of big names with military might can keep the regulators off your back?

Holmes will pay a $500,000 penalty and give back the 18.9 million shares in Theranos that she managed to collect along the way. She is also set to be banned from serving as an officer or director of a public company for 10 years. It’s a major fall from grace for a high-school drop-out who became a fast start of Silicon Valley before falling from grace just as quickly.

Holmes, 34, won’t be the only target, either. The SEC said it would also pursue Balwani, noting that this was a “two-person operation, where Holmes and Balwani exclusively controlled Theranos. They were responsible for all of the misconduct alleged in this compliant.”

Neither Theranos nor Holmes has admitted or denied the SEC allegations against them.

By Jan Bauer for Safehaven.com 

More Top Reads From Safehaven.com:

Back to homepage

Leave a comment

Leave a comment